Page 3 - RP-AUGUST-2020

When choosing a tablet to temporarily When choosing a tablet to temporarily WhehlpenrecliheoveosOinAg aflatraeb-luept tpoatienm, sptaorat rily help relieve OA flare-up pain, start When choosing a tablet to1-7temporarily hweiltph rbealileavneceOdApaflainrer-eulipefp. ain, start with balanced pain relief.1-7 help relieve OA flare-up p1-a7 in, start with balanced pain relief. 1-7 wNituhrboafelanc4e0d0paDinoureblilef. Strength Nurofen 400 Double Strength Nofuferos fpeonwe4r0fu0l aDnotiu-inbfllaemSmtraetonrgytphain offers powerful anti-inflammatory pain Nurofen 400 Double Strength orefflierfsfpoorwupertfoul8anhtoi-uinrsfl,aimnmjuastory pain relief for up to 8 hours, in just offers po2w-4 erful anti-inflammatory pain r1eltiaebflfeotr.upPltuos,8ithiosuwrse,llintojluesrtatedby 1 tablet.2-4 Plus, it is well tolerated by relief for2-u4 p to 8 hours, in just ^5-7 1thetasbtloemt.acPhluws,heitnistawkelnl taosledrairtecdtebdy. the stom2a-4ch when taken as directed.^5-7 1 tablet. Plus, it is well tolerated by^5-7 the stomach when taken as directed. the stomach when taken as directed.^5-7 MAKE THE MOVE TO NUROFEN MAKE THE MOVE TO NUROFEN MAKE THE MOVE TO NUROFEN MAKE THE MOVE TO NUROFEN Ask your pharmacist – they must decide if this product is right for you. Ask your pharmacist – they must decide if this product is right for you. AInsckoryroeucrt upsheacrmoualcdisbt e– hthaerymfmuul.sFt odretchideeteifmtphiosraproydrueclitefisorfigphatinfo. r you. Incorrect use could be harmful. For the temporary relief of pain. Ask your pharmacist – they must decide if this product is right for you. Incorrect use could be harmful. For the temporary relief of pain. Incorrect use could be harmful. For the temporary relief of pain. ^When taken as directed in an over-the-counter setting in people without contraindications/precautions. OA: osteoarthritis. ^When taken as directed in an over-the-counter setting in people without contraindications/precautions. OA: osteoarthritis. References: 1. The Royal Australian College of General Practitioners. Guideline for the management of knee and hip osteoarthritis. 2nd edn. East Melbourne, ^RVWeicf:heRerAneCtnaGkcePe,ns2:a0s1d.8Ti.rhe2ec.tReMdoeyihanliasAcnuhosDtvreRarl-eiatthnael-C.cColuliengteTerhoesefrtG2ti0neg1n0einr;a3pl2eP(6orap):cl1eti0twi3oi3nth-e1orsu0.t4Gc9ou.ni3dtr.ealMinaedlimfcoasrtirtohnmes/mKpaernetacaagl.ueCtmiolienstT.hoOefrAk1n:e9oe9st9ae;on2ad1r(ht1hipr0it)oi:s1s.t6e5o3a-r1th6r6iti3s.42n.dMeadlmn.stEraomst MKeltbaolu.rCnlein, V T h i c e : r R 2 A 0 C 0 G 4 ; P 2 , 6 2 ( 0 5 1 ) : 8 6 . 6 2 7 . - 6 M 7 e 9 h . l i 5 s c . h M D o R o r e e t a N l . e C t l a i n l . T C h l e i n r 2 D 0 r u 1 g 0 ; I n 3 v 2 e ( s 6 t ) 1 : 1 9 0 9 3 9 3 ; 1 - 1 8 0 : 8 4 9 9 – . 9 3 8 . . M 6 a . l R m a s m t r o p m a l K P e e t t a a l l . . C J I l i n n t MT h e e d r 1 R 9 e s 9 9 2 ; 0 2 0 1 2 ( 1 ; 3 0 0 ) : : 1 3 6 0 5 1 3 – 3 - 1 0 6 8 6 . 3 7 . . 4 V . a M r r a a s l m s i s G t r o e m t a K l . e A t d a v l . T C h l e i n r References: 1. The Royal Australian College of General Practitioners. Guideline for the management of knee and hip osteoarthritis. 2nd edn. East Melbourne, ^When taken as directed in an over-the-counter setting in people without contraindications/precautions. OA: osteoarthritis. T 2 h 0 e 1 r 9 2 ; 0 d 0 o 4 i : ; 2 1 6 0 ( . 5 1 ) 0 : 6 0 6 7 7 / - s 6 1 7 2 9 3 . 2 5 5 . - 0 M 1 o 9 o - r 0 e 1 N1 4 e 4 t - a 9 l . . C l i n D r u g I n v e s t 1 9 9 9 ; 1 8 : 8 9 – 9 8 . 6 . R a m p a l P e t a l . J I n t M e d R e s 2 0 0 2 ; 3 0 : 3 0 1 – 3 0 8 . 7 . V a r r a s s i G e t a l . A d v T h e r Vic: RACGP, 2018. 2. Mehlisch DR et al. Clin Ther 2010;32(6):1033-1049. 3. Malmstrom K et al. Clin Ther 1999;21(10):1653-1663. 4. Malmstrom K et al. Clin R2e0f1e9r;ednoci:e1s0:.10. 0Th7e/sR1o2y3a2l A5-u0s1tr9a-li0a1n1C4o4l-l9eg. e of General Practitioners. Guideline for the management of knee and hip osteoarthritis. 2nd edn. East Melbourne, T®heNrU2R0O04FE;2N6(is5)a:6re6g7i-s6te7r9e.d5tr.aMdeomoraerkNoefthael.RCelcinkiDttrBuegncInkviseesrt 1G9ro9u9p;1o8f:C89o–m9p8a.n6ie.sR.aLemvpeal 4l P7,e6t8a0l.GJ IenotrMgedStR,eSsy2d0ne0y22;30:300, N1–S3W08A.u7s.trVaalirar.aPsrseipGaeretdalM. Aadyv2T0h2e0r. Vic: RACGP, 2018. 2. Mehlisch DR et al. Clin Ther 2010;32(6):1033-1049. 3. Malmstrom K et al. Clin Ther 1999;21(10):1653-1663. 4. Malmstrom K et al. Clin 2®0N1U9;RdOoFi:EN10i.s1a00re7g/ist1e2re3d2t5ra-0d1e9m-a0r1k1o4f4th-9e.Reckitt Benckiser Group of Companies. Level 47, 680 George St, Sydney 2000, NSW Australia. Prepared May 2020. CHPAUS 31635-0520 Ther 2004;26(5):667-679. 5. Moore N et al. Clin Drug Invest 1999;18:89–98. 6. Rampal P et al. J Int Med Res 2002;30:301–308. 7. Varrassi G et al. Adv Ther ®NUROFEN is a registered trademark of the Reckitt Benckiser Group of Companies. Level 47, 680 George St, Sydney 2000, NSW Australia. Prepared May 2020. 2019; doi: 10.1007/s12325-019-01144-9. CHPAUS 31635-0520 CHPAUS 31635-0520 ®NUROFEN is a registered trademark of the Reckitt Benckiser Group of Companies. Level 47, 680 George St, Sydney 2000, NSW Australia. Prepared May 2020. CHPAUS 31635-0520 FIRST-LINE FIRST-LINE FIRST-LINE FIRST-LINE FOR A FOR A FOR A FOR A REASON1 REASON1 REASON1 REASON1